AR and prostate cancer: Metastatic prostate cancer is treated with androgen deprivation therapy (ADT), most often gonadotropin-releasing hormone (GnRH) agonists, to block testosterone synthesis and inhibit activation of the androgen receptor (AR), a mechanism critical for survival and proliferation of prostate cancer cells.